{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:40:18Z","timestamp":1793328018845,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04559-4","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:03:27Z","timestamp":1789484607000},"page":"3302-3312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Xinghao","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heshui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoxing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-9553","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haige","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"4559_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","volume":"6","author":"JK Lee","year":"2022","unstructured":"Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. npj Precis. Oncol. 6, 91 (2022).","journal-title":"npj Precis. Oncol."},{"key":"4559_CR2","doi-asserted-by":"publisher","first-page":"e2100245","DOI":"10.1200\/PO.21.00245","volume":"6","author":"ME Salem","year":"2022","unstructured":"Salem, M. E. et al. Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers. JCO Precis. Oncol. 6, e2100245 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"4559_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00432-025-06118-9","volume":"151","author":"L Wu","year":"2025","unstructured":"Wu, L. et al. Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China. J. Cancer Res. Clin. Oncol. 151, 94 (2025).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"4559_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"4559_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153\u2013168 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"4559_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","volume":"8","author":"A Yousef","year":"2024","unstructured":"Yousef, A. et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precis. Oncol. 8, 27 (2024).","journal-title":"npj Precis. Oncol."},{"key":"4559_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s44276-025-00188-5","volume":"3","author":"E Osterlund","year":"2025","unstructured":"Osterlund, E. et al. KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts. BJC Rep. 3, 72 (2025).","journal-title":"BJC Rep."},{"key":"4559_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.annonc.2022.07.005","volume":"33","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann. Oncol. 33, 1029\u20131040 (2022).","journal-title":"Ann. Oncol."},{"key":"4559_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","volume":"12","author":"MH Hofmann","year":"2022","unstructured":"Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 12, 924\u2013937 (2022).","journal-title":"Cancer Discov."},{"key":"4559_CR10","doi-asserted-by":"publisher","first-page":"1394702","DOI":"10.3389\/fonc.2024.1394702","volume":"14","author":"J Lokhandwala","year":"2024","unstructured":"Lokhandwala, J., Smalley, T. B. & Tran, T. H. Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance. Front. Oncol. 14, 1394702 (2024).","journal-title":"Front. Oncol."},{"key":"4559_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"4559_CR12","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4559_CR13","doi-asserted-by":"publisher","first-page":"425082","DOI":"10.1200\/JCO.2023.41.36_suppl.425082","volume":"41","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation. J. Clin. Oncol. 41, 425082\u2013425082 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4559_CR14","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.lungcan.2024.107886","volume":"194","author":"Y Oya","year":"2024","unstructured":"Oya, Y., Imaizumi, K. & Mitsudomi, T. The next-generation KRAS inhibitors\u2026what comes after sotorasib and adagrasib?. Lung Cancer 194, 107886 (2024).","journal-title":"Lung Cancer"},{"key":"4559_CR15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","volume":"19","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Efficacy and safety of KRASG12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study. J. Thorac. Oncol. 19, 1630\u20131639 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"4559_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig, M. N. et al. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955\u2013967 (2023).","journal-title":"Trends Cancer"},{"key":"4559_CR17","doi-asserted-by":"publisher","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","volume":"8","author":"C Norton","year":"2025","unstructured":"Norton, C. et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw. Open. 8, e2453588 (2025).","journal-title":"JAMA Netw. Open."},{"key":"4559_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102502","volume":"113","author":"F Dayyani","year":"2023","unstructured":"Dayyani, F., Macarulla, T., Johnson, A. & Wainberg, Z. A. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: a systematic literature review. Cancer Treat. Rev. 113, 102502 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"4559_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.hoc.2016.08.002","volume":"31","author":"G Durm","year":"2017","unstructured":"Durm, G. & Hanna, N. Second-line chemotherapy and beyond for non-small cell lung cancer. Hematol. Oncol. Clin. North Am. 31, 71\u201381 (2017).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"4559_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/CEG.S390655","volume":"17","author":"R Imperial","year":"2024","unstructured":"Imperial, R. et al. Second-line treatment of pancreatic adenocarcinoma: shedding light on new opportunities and key talking points from clinical trials. Clin. Exp. Gastroenterol. 17, 121\u2013134 (2024).","journal-title":"Clin. Exp. Gastroenterol."},{"key":"4559_CR21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.37349\/etat.2024.00277","volume":"5","author":"K Wang","year":"2024","unstructured":"Wang, K., Leyba, A. & Hsu, R. Addressing the unmet need in NSCLC progression with advances in second-line therapeutics. Explor. Target. Antitumor Ther. 5, 1297\u20131320 (2024).","journal-title":"Explor. Target. Antitumor Ther."},{"key":"4559_CR22","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"4559_CR23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/jcm15020873","volume":"15","author":"R Pradeep","year":"2026","unstructured":"Pradeep, R. et al. KRAS inhibition in pancreatic ductal adenocarcinoma. J Clin Med. 15, 873 (2026).","journal-title":"J Clin Med."},{"key":"4559_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell 42, 1286\u20131300 e1288 (2024).","journal-title":"Cancer Cell"},{"key":"4559_CR25","doi-asserted-by":"crossref","unstructured":"Arbour, K. C. et al. Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. Cancer Res. 85, abstr. CT019 (2025).","DOI":"10.1158\/1538-7445.AM2025-CT019"},{"key":"4559_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","volume":"394","author":"W Park","year":"2026","unstructured":"Park, W. et al. Setidegrasib in advanced non\u2013small-cell lung cancer and pancreatic cancer. N. Engl. J. Med. 394, 1409\u20131420 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4559_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118555","volume":"305","author":"V Kumar","year":"2026","unstructured":"Kumar, V. et al. An overview of KRAS G12D inhibitors: expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities. Eur. J. Med. Chem. 305, 118555 (2026).","journal-title":"Eur. J. Med. Chem."},{"key":"4559_CR28","doi-asserted-by":"publisher","first-page":"abstr.3318","DOI":"10.1158\/1538-7445.AM2024-3318","volume":"84","author":"F Yan","year":"2024","unstructured":"Yan, F. et al. GFH375 (VS-7375): an oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy. Cancer Res. 84, abstr.3318 (2024).","journal-title":"Cancer Res."},{"key":"4559_CR29","doi-asserted-by":"crossref","unstructured":"Ai, X. et al. A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. J. Clin. Oncol. 43, abstr. 3013 (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.3013"},{"key":"4559_CR30","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin, B. M. et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N. Engl. J. Med. 394, 1790\u20131802 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4559_CR31","doi-asserted-by":"publisher","unstructured":"O\u2019Reilly, E. M. et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2605555 (2026).","DOI":"10.1056\/NEJMoa2605555"},{"key":"4559_CR32","doi-asserted-by":"crossref","unstructured":"Pachter, J. A. et al. GFH375 (VS-7375): an oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models. Cancer Res. 85, abstr. 4394 (2025).","DOI":"10.1158\/1538-7445.AM2025-4394"},{"key":"4559_CR33","doi-asserted-by":"crossref","unstructured":"Coma, S. et al. VS-7375: an oral, selective KRAS G12D dual ON\/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents. Cancer Res. 86, abstr. 7100 (2026).","DOI":"10.1158\/1538-7445.AM2026-7100"},{"key":"4559_CR34","doi-asserted-by":"crossref","unstructured":"Brandon, L. et al. VS-7375, a non-covalent dual ON\/OFF KRASG12D inhibitor, displays superior activity to ON-only KRASG12D inhibitors in preclinical models of pancreatic cancer. Cancer Res. 86, abstr. LB197 (2026).","DOI":"10.1158\/1538-7445.AM2026-LB197"},{"key":"4559_CR35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S1556-0864(25)00194-7","volume":"20","author":"M Majem","year":"2025","unstructured":"Majem, M. et al. LBA1: first-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. J. Thorac. Oncol. 20, S1 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"4559_CR36","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"4559_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-024-01948-4","volume":"9","author":"J Cui","year":"2024","unstructured":"Cui, J. et al. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduct. Target. Ther. 9, 248 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"4559_CR38","doi-asserted-by":"publisher","first-page":"S558","DOI":"10.1016\/j.annonc.2025.08.1484","volume":"36","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. 915O KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: a phase I trial. Ann. Oncol. 36, S558\u2013S559 (2025).","journal-title":"Ann. Oncol."},{"key":"4559_CR39","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"AI Spira","year":"2025","unstructured":"Spira, A. I. et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J. Clin. Oncol. 43, 724\u2013724 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4559_CR40","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4559_CR41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio, V. et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10, 1129\u20131139 (2020).","journal-title":"Cancer Discov."},{"key":"4559_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012).","journal-title":"Nature"},{"key":"4559_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccell.2025.10.010","volume":"44","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell 44, 77\u201393.e8 (2026).","journal-title":"Cancer Cell"},{"key":"4559_CR44","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger, R. et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. 14, 982\u2013993 (2024).","journal-title":"Cancer Discov."},{"key":"4559_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","volume":"30","author":"Y Kuboki","year":"2024","unstructured":"Kuboki, Y. et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat. Med. 30, 265\u2013270 (2024).","journal-title":"Nat. Med."},{"key":"4559_CR46","unstructured":"Garrido-Laguna, I. et al. LB-B008, A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. Mol. Cancer Ther. 24 abstr. LB-B008 (2025)."},{"key":"4559_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22125-z","volume":"12","author":"JH Cook","year":"2021","unstructured":"Cook, J. H. et al. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 12, 1808 (2021).","journal-title":"Nat. Commun."},{"key":"4559_CR48","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/cncr.30677","volume":"123","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK\/ROS1 fusion-positive non-small cell lung cancer. Cancer 123, 2927\u20132935 (2017).","journal-title":"Cancer"},{"key":"4559_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep11348","volume":"5","author":"HQ Ying","year":"2015","unstructured":"Ying, H. Q. et al. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. Sci. Rep. 5, 11348 (2015).","journal-title":"Sci. Rep."},{"key":"4559_CR50","doi-asserted-by":"publisher","first-page":"e21055","DOI":"10.1200\/JCO.2022.40.16_suppl.e21055","volume":"40","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. The association between BIM deletion polymorphism and treatment efficacy of PD-1\/PD-L1 inhibitors in advanced NSCLC. J. Clin. Oncol. 40, e21055 (2022).","journal-title":"J. Clin. Oncol."},{"key":"4559_CR51","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-24-1970","volume":"85","author":"GZ Murimwa","year":"2025","unstructured":"Murimwa, G. Z. et al. SMAD4 deficiency promotes pancreatic cancer progression and confers susceptibility to TGF\u03b2 inhibition. Cancer Res. 85, 2987\u20132996 (2025).","journal-title":"Cancer Res."},{"key":"4559_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189220","volume":"1879","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. New insight into the role of SMAD4 mutation\/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochim. Biophys. Acta Rev. Cancer 1879, 189220 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"4559_CR53","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","volume":"24","author":"KC Arbour","year":"2018","unstructured":"Arbour, K. C. et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin. Cancer Res. 24, 334\u2013340 (2018).","journal-title":"Clin. Cancer Res."},{"key":"4559_CR54","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018).","journal-title":"Cancer Discov."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04559-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:03:32Z","timestamp":1789484612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4559"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04559-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L. reports research funding from AstraZeneca, Hutchison, Bristol Myers Squibb (BMS), Heng Rui, BeOne Medicines, Roche and Hansoh Pharma; consulting fees from AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere, Zai Lab, GenomiCare Consulting, Yuhan Corporation, PRIME Oncology, Menarini Group and Roche; and honorarias as an invited speaker from AstraZeneca, Roche, Hansoh Pharma and Hengrui Therapeutics. Y. Du reports research funding from Innovent Biologics and Anke Biotechnology. Y.W., H.S., H. Zhu, C.Z., S.W., Z.C. and L.T. report employment and stock or stock options with GenFleet Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}